PCAS: Q1 2020 net sales
Ecully, France - May 12, 2020
Q1 2020 NET SALES
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its consolidated net sales as at March 31, 2020.
The PCAS Group had generated consolidated net
sales of €53.3 million as of March 31, 2020, representing an
increase of 5.3% compared to the same period during the previous
financial year (+4.5% at a constant exchange rate). The first
quarter was not affected by the Covid-19 crisis.
In millions of euros |
|
2020 |
|
2019 |
|
% change |
|
2020
At a constant exchange rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
Sales
as of 31 March |
|
53.3 |
|
50.6 |
|
5.3% |
|
52.9 |
|
4.5% |
Pharmaceutical Synthesis |
|
36.2 |
|
29.9 |
|
21.3% |
|
35.9 |
|
20.3% |
Fine Specialty Chemicals |
|
17.1 |
|
20.8 |
|
-17.7% |
|
17.0 |
|
-18.1% |
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business in Health
generated €36.2 million, up 21.3% on 2019 (20.3% at a constant
exchange rate). The first quarter of 2019 had been affected by
operational difficulties at one of our sites and shortages in raw
material supplies. The first quarter of 2020 shows that our
production facilities are gradually back to normal operation and we
are confident in our ability to meet the increase in demand.
Fine Specialty Chemicals
Net sales of fine specialty chemicals amounted
to €17.1 million, which was down 17.7% compared to 2019 (-18.1% at
a constant exchange rate). During the first quarter, the
Electronics business was stable, but the Lubricants and Fine
Chemicals activities experienced a sharp decrease due to the
economic downturn since mid-2019 for Lubricants and a slower start
to the year than in 2019 for Fine Chemicals.
Outlook
As mentioned in our press release on March 31,
2020, the global health crisis relating to the coronavirus is
changing by the day, and there is still a grey area surrounding its
duration, its extent and its effects on companies' production lines
and consumption in general.
The PCAS Group has not seen any major impacts on
its business activities and earnings to date. However, it is hard
to anticipate the potential impacts in the medium term. This crisis
calls for cautious measures. Due to the exceptional circumstances,
the Group has suspended its financial targets and its strategic
business objectives until the situation becomes clearer.
NEXT FINANCIAL DISCLOSURE
Net sales for H1 2020 on July 23, 2020
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 10% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €200.9 million in 2019 and employs close to 1 100
people in six countries.
To find out more about PCAS: www.pcas.com
PCAS |
NewCap |
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier Financial
communication and investor relation |
Tel.: +33 1 69 79 60 00www.pcas.com |
Tel.: +33 1 44 71 98 53pcas@newcap.eu |
- PCAS_Q1 revenue_eng_ final
PCAS (EU:PCA)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
PCAS (EU:PCA)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024